Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia
Natasha Kekre,
Ying Zhang,
Mei-Jie Zhang,
Jeanette Carreras,
Parvez Ahmed,
Paolo Anderlini,
Elias Hallack Atta,
Mouhab Ayas,
Jaap Jan Boelens,
Carmem Bonfim,
H. Joachim Deeg,
Neena Kapoor,
Jong-Wook Lee,
Ryotaro Nakamura,
Michael A. Pulsipher,
Mary Eapen,
Joseph H. Antin
Affiliations
Natasha Kekre
Division of Hematology, The Ottawa Hospital, ON, Canada
Ying Zhang
Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA
Mei-Jie Zhang
Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA;Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Jeanette Carreras
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Parvez Ahmed
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan
Paolo Anderlini
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Elias Hallack Atta
Instituto Nacional de Câncer, Rio de Janeiro, Brazil
Mouhab Ayas
Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
Jaap Jan Boelens
Department of Pediatrics, University Medical Center Utrecht, The Netherlands
Carmem Bonfim
Hospital de Clinicas, Federal University of Parana, Curitiba, Brazil
H. Joachim Deeg
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Neena Kapoor
Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Hospital Los Angeles, CA, USA
Jong-Wook Lee
BMT Center, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Ryotaro Nakamura
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
Michael A. Pulsipher
Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Hospital Los Angeles, CA, USA
Mary Eapen
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Joseph H. Antin
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
For treatment of severe aplastic anemia, immunosuppressive therapy with horse antithymocyte globulin results in superior response and survival compared with rabbit antithymocyte globulin. This relative benefit may be different in the setting of transplantation as rabbit antithymocyte globulin results in more profound immunosuppression. We analyzed 833 severe aplastic anemia transplants between 2008 and 2013 using human leukocyte antigen (HLA)-matched siblings (n=546) or unrelated donors (n=287) who received antithymocyte globulin as part of their conditioning regimen and bone marrow graft. There were no differences in hematopoietic recovery by type of antithymocyte globulin. Among recipients of HLA-matched sibling transplants, day 100 incidence of acute (17% versus 6%, P
